Sign In
Buy SHIEF
$0.0800
+0 (+0%)
At Close: Jun 02, 2026
Shield Therapeutics completes fundraise
03:40am, Wednesday, 14'th Dec 2022
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said it has raised US$18.5mln in an oversubscribed placing and subscription, conditional on shareholder approval, with a total of over 251mln new ordin
Shield Therapeutics agrees US partnership to promote Accrufer, launches equity funding
02:59am, Tuesday, 13'th Dec 2022
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) announced an equity fundraising and a separate, multi-year deal to co-commercialisation its Accrufer iron therapy with Viatris Inc, which could provide u
Shield Therapeutics' lead product Accrufer expected to gain Korean regulatory approval in 2023
03:39am, Monday, 31'st Oct 2022
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said its iron deficiency product Accrufer/Ferracru is expected to secure regulatory approval in the Republic of Korea next year, after the Korean Food an
Shield Therapeutics' lead product Accrufer® has shelf-life extended to 48 months
04:09am, Thursday, 27'th Oct 2022
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s iron deficiency product Accrufer® has had its shelf life extended from 36 months to 48 months following approval from the US Food and Drug Administrat
Peel Hunt thinks the commercial prospects for Shield Therapeutics' Accrufer anaemia treatment remain "very good"
10:21am, Thursday, 08'th Sep 2022
Analysts at Peel Hunt think that the commercial prospects for Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s Accrufer anaemia treatment "remain very good", noting that prescriptions are building as
Shield Therapeutics revenues climb as US sales ramp up
03:40am, Thursday, 08'th Sep 2022
Shield Therapeutics' interim revenues jumped by 300% as US sales of its anaemia treatment Accrufer started to ramp up. Revenues rose to £2mln (£0.5mln) in the half year to end-June 2022, of which £
Shield Therapeutics completes the formalities on US$10mln loan
03:23am, Monday, 01'st Aug 2022
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said it had completed the formalities related to a US$10mln provided by shareholder AOP Health International Management. AOP in turn has exercised its op
Shield Therapeutics partner makes new drug submission in Canada
02:23am, Thursday, 14'th Jul 2022
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said KYE Pharmaceuticals, its licensing partner in Canada, has made a new drug submission for iron deficiency treatment Accrufer. The regulator is expect
Shield Therapeutics off to a solid start in 2022 with Acrrufer prescriptions rising sharply
02:53am, Thursday, 30'th Jun 2022
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) saw prescriptions for its Accrufer iron deficiency treatment double quarter-on-quarter in the first three months of 2022. The company said that after a
Shield Therapeutics partner submits iron deficiency drug for approval in Canada
03:22am, Monday, 21'st Mar 2022
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said partner KYE Pharmaceuticals Inc has made a new drug submission to the authorities in Canada for Accrufer, the former's iron deficiency drug. If appr
Shield Therapeutics PLC on track; starting to gain traction in the US
02:52am, Thursday, 17'th Feb 2022
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said its 2021 revenues would be in line with expectations at £1.5mln as it made the first sales of its breakthrough drug for iron deficiency. America is
Shield Therapeutics signs Canada licence agreement for Accrufer with KYE Pharmaceuticals
03:04am, Wednesday, 05'th Jan 2022
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) announced an exclusive licence agreement with KYE Pharmaceuticals Inc. for the development and commercialisation of its iron deficiency treatment Accrufe
Shield Therapeutics says 40mln patients in US have access to iron deficiency treatment
03:17am, Thursday, 16'th Dec 2021
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) now has access to 40mln commercial patients in the US for its breakthrough iron deficiency treatment. This is because it successfully secured payer cover
Shield Therapeutics expands patient access to iron deficiency treatment
03:16am, Thursday, 16'th Dec 2021
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) now has access to 40mln commercial patients in the US for its breakthrough iron deficiency treatment. This is because it successfully secured payer cover
Shield Therapeutics rapidly expanding patient access for its iron deficiency product
02:56am, Thursday, 16'th Dec 2021
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) now has access to 40mln commercial patients in the US for its breakthrough iron deficiency treatment. This is because it successfully secured payer cover
